Loading...
•
Jun 30, 2021
Cabaletta Bio Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Key Takeaways
Cabaletta Bio reported their Q2 2021 financial results. Key highlights include no clinically relevant adverse events observed in the first patient cohort of the DesCAARTes™ clinical trial for DSG3-CAART and remaining on track to submit an IND to the FDA for MuSK-CAART.
Observed no clinically relevant adverse events in the first, low-dose patient cohort of the DesCAARTes™ clinical trial for DSG3-CAART.
Remain on track to submit an IND to the FDA for MuSK-CAART.
Expect to conduct a pre-IND meeting with the FDA to discuss the development path for PLA2R-CAART in the second half of 2021.
Cash, cash equivalents and investments as of June 30, 2021, will enable it to fund its operating plan through at least the fourth quarter of 2022.
Forward Guidance
Cabaletta Bio expects to fund its operating plan through at least the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...